Myeloid cell Rap1a promotes tumor inflammation and growth.

<p>(A) Tumor volume and (B) weight of LLC tumors grown in WT mice transplanted with WT or Rap1a−/− bone marrow (n = 10); *P = 0.001 to 0.003, WT vs Rap1a−/− BM, as determined by ANOVA. (C) Percentage of CD11b+Gr1+ tumor-infiltrating myeloid cells in WT and Rap1a−/− bone marrow transplanted (BMT) tumors, *P<0.01, Rap1a−/− vs WT (ANOVA). (D) Percentage of CD11b+Gr1lo monocytic and CD11b+Gr1hi granulocytic lineage cells in WT and Rap1a−/− BMT tumors, *P<0.01 Rap1a−/− vs WT (ANOVA). (E) Representative FACs profiles from D, with upper quadrant corresponding to CD11b+Gr1hi granulocytic and lower quadrant corresponding to CD11b+Gr1lo monocytic lineage cells. (F) Percentage of F4/80+ tumor-infiltrating myeloid cells in WT and Rap1a−/− BMT tumors, *P<0.01 Rap1a−/− vs WT (ANOVA). (G) Representative images of tumor cryosections that were immunostained to detect F4/80+ macrophages (red) and CD31+ blood vessels (green) and counterstained with Dapi. Scale bar = 40 µM. (H) Quantification of F4/80+ pixels/field in cryosections from G, *P<0.01 Rap1a−/− vs WT. (I) CD31+ pixels/field in cryosections from G, *P<0.01 Rap1a−/− vs WT.